Federal Register / Vol. 87, No. 117 / Friday, June 17, 2022 / Notices 36505 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Pilot Plan for the Interim Local Health 

Department Strategy for Response, 

Control, and Prevention of Healthcare 

Associated Infections (HAI) and 

Antibiotic Resistance (AR)—New— 

National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC) Division of Healthcare 

Quality Promotion (DHQP) recently 

developed an Interim Local Health 

Department Strategy for Response, 

Control, and Prevention of Healthcare 

Associated Infections (HAI) and 

Antibiotic Resistance (AR). CDC’s vision 

is to strengthen local and regional 

capacity to respond to, control, and 

prevent HAI/AR across all healthcare 

settings and in the community by 

supporting enhanced coordination 

between state and local partners and by 

promoting local public health, 

healthcare, and community partner 

networks. This vision can be achieved 

with collaboration between local, state, 

and federal public health entities, and 

partners. This strategy aims to 

strengthen local health departments 

(LHD) by focusing on three main goals: 

(1) growing strong partner networks; (2) 

building internal operational capacity; 

and (3) expanding the scope of 

programmatic activities to effectively 

address HAI/AR in their jurisdictions. 

CDC’s next steps include piloting the 

strategy with local health departments 

in part through a cooperative agreement 

with the National Association for 

County and City Health Officials 

(NACCHO) and is proposing this data 

collection to gather information from 

LHDs during that pilot phase. The 

strategy was developed to highlight and 

support the important role LHDs play in 

preventing, responding to, and 

controlling HAI and AR related events. 

The HAI/AR activities that are 

conducted by LHDs vary widely and 

depend on many factors such as staff 

capacity and expertise, governance 

structures and public health authorities, 

prevalence of emerging HAI/AR 

diseases, types, and organization of 

healthcare facilities in the jurisdiction, 

population demographics, local 

relationships, and nature of 

collaborations with the state HAI/AR 

program. While the specific activities 

and responsibilities of LHDs will vary, 

the unique roles and assets of LHDs 

make them critical players in the 

prevention and control of HAI/AR 

infections. LHDs can build relationships 

in their local communities and may be 

well-positioned to understand and 

respond to the health needs of their 

communities. There is much to be 

learned and many best practices to be 

shared from LHD working in HAI/AR. 

Engaging with LHDs is essential for 

DHQP to connect to other priority areas 

such as focusing on rural areas, 

healthcare preparedness, and health 

equity considerations. Additionally, a 

local engagement strategy will help 

DHQP expand their activities to focus 

on connecting with LHDs that directly 

work between healthcare and public 

health groups, especially to continue 

work and partnerships begun by 

COVID–19 task forces. 

The data collection and subsequent 

data analysis will identify themes and 

commonalities that will be used to make 

updates to the strategy and identify 

areas of support for LHDs seeking to 

grow their capacity for HAI/AR 

activities. CDC requests OMB approval 

for an estimated 390 annual burden 

hours. There are no costs to respondents 

other than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

(in hours) 

Voluntary LHD Participants ............... LHD HAI/AR Strategy Pilot Feedback Form.30 1 4 120 

Voluntary LHD Participants ............... LHD HAI/AR Strategy Pilot Interview 

Guide Survey.

30 1 1 30 

Voluntary LHD Participants ............... LHD HAI/AR Strategy Pilot Survey 

for Review and Implement.

30 1 2 60 

NACCHO CoAg LHD Participants .... LHD HAI/AR Strategy Pilot Survey .. 30 1 2 60 

NACCHO CoAg LHD Participants .... LHD HAI/AR Strategy Pilot Feedback Form.30 1 4 120 

Total ........................................... ........................................................... ........................ ........................ ........................ 390 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–13095 Filed 6–16–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–22–21EX] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled ‘‘Baseline of 

Injury and Psychosocial Stress for 

Applied Behavior Analysis Workers’’ to 

the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on May 7, 2021 to obtain 

comments from the public and affected 


lotter on DSK11XQN23PROD with NOTICES1
36506 Federal Register / Vol. 87, No. 117 / Friday, June 17, 2022 / Notices 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

Baseline of Injury and Psychosocial 

Stress for Applied Behavior Analysis 

Workers—New—National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

As mandated in the Occupational 

Safety and Health Act of 1970 (Pub. L. 

91–596), the mission of NIOSH is to 

conduct research and investigations on 

occupational safety and health. This 

project will focus on obtaining a better 

understanding of the injuries sustained 

and psychosocial stressors experienced 

by applied behavior analysis workers. 

Applied behavior analysis (ABA) is a 

principle intervention for increasing 

appropriate behaviors and decreasing 

inappropriate behaviors exhibited by 

children, adolescents, and adults with 

developmental disorders. As of August 

2020, there were more than 120,000 

ABA workers credentialed by the 

Behavior Analysis Certification Board. 

ABA workers, which include Board 

Certified Behavior Analysts and 

Registered Behavior Technicians, are 

responsible for planning and 

implementing behavior-focused 

treatments in schools, clinics, homes, 

and hospitals. 

There is no current Standard 

Occupational Classification category for 

ABA workers. The absence of an 

occupational category means that 

estimates of injury among this group are 

based on statistics from existing 

occupational groups and anecdotal 

evidence from practitioners. ABA 

workers are in a variety of occupational 

categories, but they often have job 

duties that make many of their 

experiences in the workplace distinct 

from other types of workers in those 

occupational categories. Whereas other 

healthcare workers usually take steps to 

mitigate violence in their work, ABA 

workers are tasked with soliciting and 

then treating (i.e., confronting) 

disruptive behavior as part of behavioral 

treatments. In addition, ABA workers 

often spend more time with clients than 

other types of workers: 25–40 hours per 

week of direct-contact services is 

common for a client. 

Some ABA workers are often in 

dangerous working environments, in 

homes and clinics, with clients who 

may sometimes behave unpredictably or 

aggressively. Despite these hazards and 

risks and despite the growing number of 

ABA workers nationally, there are no 

data on frequency and severity of 

injuries among this population of 

workers, and the only evidence is 

anecdotal in nature. The goal of the 

study is to collect data on the burden of 

work-related injuries among ABA 

workers to begin to fill the gaps in the 

research and obtain a better 

understanding of the hazards and risks 

they encounter. 

This study consists of a one-time 10- 

minute survey targeted to credentialed 

ABA workers. Survey respondents will 

include individuals currently 

credentialed by the Behavior Analysis 

Certification Board. This includes 

registered behavior technicians, board 

certified assistant behavior analysts, 

board certified behavior analysts, and 

board-certified behavior analysts— 

doctoral. The survey consists of 

questions related to demographics, 

organizational safety climate, injuries, 

safety training, and burnout. A brief 

message and a link to complete the 

online survey will be sent by email. 

Based on previous research with 

internet surveys, we anticipate an 

approximate response rate of 10%. The 

etiologic approach will provide data to 

assess important characteristics of the 

population; guide control measures; 

serve as a quantitative basis to define 

objectives and specific priorities; and 

inform the designing, planning, and 

evaluation of future interventions. 

CDC requests OMB approval for an 

estimated 4,000 annual burden hours. 

There are no costs to respondents other 

than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Board Certified Behavior Analysts (BCBA, BCBA–D, and BCaBA) ............. Survey .............. 8,640 1 10/60 

Registered Behavior Technicians (RBT) ...................................................... Survey .............. 15,360 1 10/60 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 117 / Friday, June 17, 2022 / Notices 36507 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–13091 Filed 6–16–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

CDC Town Hall Meeting on Laboratory 

Biosafety—Use of Laboratory 

Instruments 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces a 

meeting regarding biosafety and 

laboratory instrumentation. 

DATES: The meeting will be held on 

Friday, June 24, 2022, from 10 a.m. to 

3:30 p.m., EDT. 

ADDRESSES: This meeting is open to the 

public through a virtual format, limited 

only by the webcast lines available. 

Registration is not required. Visit the 

CDC Safe Labs website for the meeting 

webcast at https://www.cdc.gov/ 

safelabs/biosafety-townhall.html. 

FOR FURTHER INFORMATION CONTACT: 

Nancy E. Cornish M.D., Center for 

Surveillance, Epidemiology and 

Laboratory Services, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Mailstop V24–3, Atlanta, 

Georgia 30329–4018; Phone: (404)498– 

2720; Email: dlsbiosafety@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The purpose of this meeting 

is to provide an overview and 

discussion on laboratory biosafety when 

using laboratory instruments to test 

human and biologic specimens. Meeting 

topics are listed in the ‘‘Matters to be 

Considered’’ section of this notice. 

Matters to be Considered: The agenda 

will include presentations and 

discussions on four topic areas: (1) 

instrument design and incorporating 

biosafety; (2) perceived risks to 

laboratory personnel and impact on 

testing; (3) independent assessment of 

risks and instrument design; and (4) a 

discussion of potential areas of 

collaboration to address issues 

discussed during the meeting. There 

will be prepared presentations, 

discussions among presenters and 

panelists, and a period for questions and 

public comments. Agenda items are 

subject to change as priorities dictate. 

Background: CDC’s Division of 

Laboratory Systems is hosting the town 

hall meeting in collaboration with 

clinical and public health laboratory 

partners, and instrument manufacturers 

to address clinical laboratory biosafety. 

The recent publication Clinical 

Laboratory Biosafety Gaps: Lessons 

Learned from Past Outbreaks Reveal a 

Path to a Safer Future (Cornish NE. et. 

al. Clinical Laboratory Biosafety Gaps: 

Lessons Learned from Past Outbreaks 

Reveal a Path to a Safer Future. Clin 

Microbiol Rev. July 2021, Vol. 34/3 

e00126–18) discussed critical gaps in 

clinical laboratory biosafety, including 

issues related to the use and 

disinfection of laboratory instruments. 

The discussion and feedback generated 

during the meeting will assist in 

evaluating current biosafety guidance 

and identify opportunities for 

improvement in clinical laboratory 

biosafety and use of laboratory 

instrumentation. This meeting is a 

listening session. Participants may 

provide individual advice or 

perspectives. CDC is not seeking 

consensus advice or recommendations 

from participants. 

Dated: June 14, 2022. 

Angela K. Oliver, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2022–13123 Filed 6–16–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2015–N–0030] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Human Drug 

Compounding Under Sections 503A 

and 503B of the Federal Food, Drug, 

and Cosmetic Act 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, Agency, or we) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension of an 

existing collection of information, and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on electronic 

reporting for outsourcing facilities. 

DATES: Submit either electronic or 

written comments on the collection of 

information by August 16, 2022. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. The https://

www.regulations.gov electronic filing 

system will accept comments until 

11:59 p.m. Eastern Time at the end of 

August 16, 2022. Comments received by 

mail/hand delivery/courier (for written/ 

paper submissions) will be considered 

timely if they are postmarked or the 

delivery service acceptance receipt is on 

or before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 


lotter on DSK11XQN23PROD with NOTICES1